Prevalence of Oncogenic Human Papillomavirus and its Association with Cervical Neoplasia

Cervical cancer ranks second in the cancer incidence structure in Uzbekistan. In 2024, 1837 new cases were identified, 1000 women died. Cervical cancer is caused by persistence papillomavirus infection, so the main factor in preventing cervical cancer is screening and vaccination against the human papillomavirus. Infection of the epithelial cells of the cervix with HPV is a necessary but insufficient factor for their malignancy. Therefore, if infection has already occurred, it is important to carry out therapeutic measures aimed at eliminating HPV from the body. One of the effective methods of complex conservative therapy is stimulation of cellular immunity using an analogue of natural purines - inosine pranobex as an immunostimulant . The antiviral effect of inosine pranobex is to suppress the replication of DNA and RNA viruses by binding to the ribosome of the cell. The immunomodulatory ability is characterized by stimulation of nonspecific immunity, increased production of interleukins, increased synthesis of antibodies, stimulation of chemotactic and phagocytic activity of monocytes, macrophages and polymorphonuclear cells. The article consolidates data from open and double-blind placebo-controlled studies of inosine pranobex , which confirmed its effectiveness in the treatment of HPV infection.